Dasabuvir/ombitasvir/paritaprevir/ritonavirAlanine aminotransferase elevation and drug resistance: 4 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1739卷 / 1期
关键词：
D O I：
10.1007/s40278-019-57749-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 109
相关论文
共 50 条
  • [21] On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
    Bean, Madelyne
    Tang, Lydia
    Kottilil, Shyam
    Beavers, Kimberly L.
    Meissner, Eric G.
    CASE REPORTS IN INFECTIOUS DISEASES, 2016, 2016
  • [22] Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs for Substance Abuse
    King, Jennifer R.
    Menon, Rajeev M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (02): : 201 - 205
  • [23] Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports
    Ponziani, Francesca Romana
    Siciliano, Massimo
    Lionetti, Raffaella
    Pasquazzi, Caterina
    Gianserra, Laura
    D'Offizi, Gianpiero
    Gasbarrini, Antonio
    Pompili, Maurizio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 70 (02) : 297 - 300
  • [24] Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
    Leung, Daniel H.
    Wirth, Stefan
    Yao, Betty B.
    Viani, Rolando M.
    Gonzalez-Peralta, Regino P.
    Jonas, Maureen M.
    Lobritto, Steven J.
    Narkewicz, Michael R.
    Soka, Etienne
    Fortuny, Claudia
    Hsu, Evelyn K.
    Del Valle-Segarra, Antonio
    Zha, Jiuhong
    Larsen, Lois
    Liu, Li
    Shuster, Diana L.
    Cohen, Daniel E.
    Rosenthall, Philip
    HEPATOLOGY COMMUNICATIONS, 2018, 2 (11) : 1311 - 1319
  • [25] Dasabuvir/ombitasvir/paritaprevir/ritonavir/ribavirin/warfarin interactionInternational normalised ratio decreased: case report
    Reactions Weekly, 2017, 1641 (1) : 106 - 106
  • [26] Dasabuvir/ombitasvir/paritaprevir/ritonavirSkin lesions, mood changes, aggressiveness and suicidal ideation: case report
    Reactions Weekly, 2016, 1626 (1) : 64 - 64
  • [27] Dasabuvir/ombitasvir/paritaprevir/ritonavirDevelopment of ombitasvir resistance in hepatitis C virus infection leading to real-life 3D therapy failure: case report
    Reactions Weekly, 2018, 1710 (1) : 112 - 112
  • [28] DRUG-DRUG INTERACTIONS OF SIROLIMUS OR EVEROLIMUS WITH THE HCV DIRECT ACTING ANTIVIRAL (DAA) COMBINATION OF OMBITASVIR, PARITAPREVIR/R AND DASABUVIR
    Zha, J.
    Badri, P.
    Shuster, D. L.
    Jiang, Q.
    Yao, B.
    Cohen, D. E.
    Dutta, S.
    Menon, R. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S93 - S94
  • [29] Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report
    Makara, Mihaly
    Sulyok, Mihaly
    Csacsovszki, Otto
    Sulyok, Zita
    Valyi-Nagy, Istvan
    JOURNAL OF CLINICAL VIROLOGY, 2015, 72 : 66 - 68
  • [30] Dasabuvir/ombitasvir/paritaprevir/ritonavir/warfarin interactionINR level increased with subsequent INR reduction: case report
    Reactions Weekly, 2019, 1774 (1) : 116 - 116
12345